Therapeutic proteins (TP) – and more specifically monoclonal antibodies – are part of the therapeutic arsenal for the treatment of several diseases, providing effective and safe therapeutic solutions for patients.
As part of the usual therapeutic practice, patients often receive drug combinations (TP/TP or TP/small molecules) and/or concomitant co-medications. Thus, drug-drug-interactions (DDIs) can be a real risk for patients. Understanding and characterizing TP DDIs should be part of standard drug development to inform labeling in cases of clinically meaningful DDIs. This will help drug developers to provide relevant recommendations for prescribers and patients.
This webinar will provide an overview of the main TP DDI mechanisms and examples of specific TP DDIs. Our expert will also present and discuss the DDI clinical pharmacology assessments during drug development according to the latest regulatory recommendations.
